Literature DB >> 34666940

Caudamins, a new subclass of protein hormones.

Bijoya Basu1, Mahim Jain2, Atul R Chopra3.   

Abstract

Hormones have traditionally been classified by their mode of biosynthetic origin. We postulate a mode of hormone biosynthesis that leads to a new subclass of protein hormones. Members of this class are derived from a cleavage event that also generates a much larger, functionally unrelated, nonhormonal protein. Here, we examine four representative members of this group: endostatin, endotrophin, asprosin, and placensin. We have named this subclass of protein hormones caudamins, from the Latin word cauda meaning 'tail'. These four caudamins have shown promise in understanding and treating diseases like metabolic syndrome and cancer. Identification of the rest of the caudamins will likely provide a plethora of drug targets for a variety of diseases.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34666940      PMCID: PMC8585694          DOI: 10.1016/j.tem.2021.09.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  53 in total

Review 1.  Integrin clipping: a novel adhesion switch?

Authors:  Manolis C Demetriou; Anne E Cress
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

2.  Placensin is a glucogenic hormone secreted by human placenta.

Authors:  Yiping Yu; Jia-Huan He; Lin-Li Hu; Lin-Lin Jiang; Lanlan Fang; Gui-Dong Yao; Si-Jia Wang; Qingling Yang; Yanjie Guo; Lin Liu; Trisha Shang; Yorino Sato; Kazuhiro Kawamura; Aaron Jw Hsueh; Ying-Pu Sun
Journal:  EMBO Rep       Date:  2020-04-24       Impact factor: 8.807

3.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

4.  Cell surface glypicans are low-affinity endostatin receptors.

Authors:  S A Karumanchi; V Jha; R Ramchandran; A Karihaloo; L Tsiokas; B Chan; M Dhanabal; J I Hanai; G Venkataraman; Z Shriver; N Keiser; R Kalluri; H Zeng; D Mukhopadhyay; R L Chen; A D Lander; K Hagihara; Y Yamaguchi; R Sasisekharan; L Cantley; V P Sukhatme
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

5.  Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

Authors:  Young-Mi Kim; Sewook Hwang; Young-Myoeng Kim; Bo-Jeong Pyun; Tae-Yoon Kim; Seung-Taek Lee; Yong Song Gho; Young-Guen Kwon
Journal:  J Biol Chem       Date:  2002-05-23       Impact factor: 5.157

6.  Altered angiogenesis in caveolin-1 gene-deficient mice is restored by ablation of endothelial nitric oxide synthase.

Authors:  Christudas Morais; Quteba Ebrahem; Bela Anand-Apte; Marie-Odile Parat
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

Review 7.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

8.  Discovery of a possible role of asprosin in ovarian follicular function.

Authors:  Excel Rio S Maylem; Leon J Spicer; Isadora Batalha; Luis F Schutz
Journal:  J Mol Endocrinol       Date:  2021-01       Impact factor: 5.098

9.  Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants.

Authors:  Megan Griffiths; Jun Yang; Allen D Everett; Jacky M Jennings; Grace Freire; Monica Williams; Melanie Nies; Sharon A McGrath-Morrow; Joseph M Collaco
Journal:  J Perinatol       Date:  2020-05-04       Impact factor: 2.521

10.  Asprosin is a centrally acting orexigenic hormone.

Authors:  Clemens Duerrschmid; Yanlin He; Chunmei Wang; Chia Li; Juan C Bournat; Chase Romere; Pradip K Saha; Mark E Lee; Kevin J Phillips; Mahim Jain; Peilin Jia; Zhongming Zhao; Monica Farias; Qi Wu; Dianna M Milewicz; V Reid Sutton; David D Moore; Nancy F Butte; Michael J Krashes; Yong Xu; Atul R Chopra
Journal:  Nat Med       Date:  2017-11-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.